Volume 17, Number 6—June 2011
CME ACTIVITY - Research
Cefepime-Resistant Pseudomonas aeruginosa
Ehimare Akhabue, Marie Synnestvedt, Mark G. Weiner, Warren B. Bilker, and Ebbing Lautenbach
Table 2
Multivariable model of risk factors for cefepime-resistant Pseudomonas aeruginosa infection, Philadelphia, PA, USA, 2001–2006*
| Variable | Unadjusted OR | Adjusted OR (95% CI) | p value |
|---|---|---|---|
| Prior use of extended-spectrum cephalosporin | 2.87 | 2.18 (1.57–3.04) | <0.001 |
| Prior use of extended-spectrum penicillin | 2.99 | 1.91 (1.22–2.99) | 0.005 |
| Prior use of quinolone | 2.61 | 1.96 (1.38–2.78) | <0.001 |
| Prior use of carbapenem | 2.74 | 1.70 (0.90–3.21) | 0.10 |
| Transfer from outside facility | 1.85 | 1.49 (1.09–2.04) | 0.01 |
| Length of hospital stay before culture | NA | 1.00 (0.99–1.01)† | 0.81 |
*OR, odds ratio; CI, confidence interval; NA, not applicable. No substantive changes were found when above analyses were limited to bloodstream isolates only.
†Odds associated with each 1-day increase in hospital stay.
Page created: September 01, 2011
Page updated: September 01, 2011
Page reviewed: September 01, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.